PHAEUROPE
PHAEUROPE is a Vienna-based non-profit umbrella patient advocacy organization representing 33 national pulmonary hypertension associations across roughly 27 European countries, delivering awareness campaigns, educational programs, capacity building, and EU-level policy advocacy for PH patients, caregivers, and clinicians.
- Company typePrivate
- Founded-
- HeadquartersVienna, Austria
- Headcount1–10
- GTM typeB2B
- OfferingServices
What PHAEUROPE does
PHAEUROPE (European Pulmonary Hypertension Association) is a Vienna-headquartered, non-profit umbrella patient advocacy organization representing 33 national pulmonary hypertension (PH) patient associations across approximately 27 European countries. Founded in the early 2000s, the organization operates with a small core staff of around 7 employees and is governed by a Board of Directors, with Gerald Fischer serving as President and Pisana Ferrari as Vice President. Its functional remit spans PH awareness, patient and healthcare-professional education, capacity building for member associations, and policy advocacy at EU institutions including the European Parliament.
The organization's product surface is fundamentally a portfolio of educational programs and awareness campaigns rather than technology products. Core offerings include the biannual Mariposa Journal, multi-stakeholder educational platforms (PH Human, Time to Talk, PH: It's Personal, Opening Lines), awareness campaigns such as the O2Kids initiative (over 1.05 million video views) and World Pulmonary Hypertension Day (6.1 million impressions in 2025), the Bel Air Center online PH platform, the Find Your Specialist directory, and the annual APHEC conference. No proprietary AI/ML technology, APIs, or commercial software products are offered.
The revenue model is non-commercial: PHAEUROPE funds its operations primarily through pharmaceutical company sponsorships (including Johnson & Johnson, AOP Health, Ferrer, MSD, Chiesi, Insmed, and several smaller PH-focused biotechs), grants (e.g., European Commission), and voluntary donations. It does not sell products or services to patients or clinicians. Its go-to-market is community-led: PHA Europe reaches patients and member associations through its federated national network, annual conferences, awareness days, capacity-building programs, and direct engagement with EU policymakers and healthcare professionals, with no traditional sales motion, pricing structure, or external investor base.
PHAEUROPE firmographics
Firmographics- Name
- PHAEUROPE
- Legal name
- European Pulmonary Hypertension Association (PHA Europe)
- Website
- https://phaeurope.org
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- PHAEUROPE is a Vienna-based non-profit umbrella patient advocacy organization representing 33 national pulmonary hypertension associations across roughly 27 European countries, delivering awareness campaigns, educational programs, capacity building, and EU-level policy advocacy for PH patients, caregivers, and clinicians.
- Ownership category
- akta.pro rank
PHAEUROPE industry classification
Industry- Product category
- Patient Advocacy Services
- NAICS
- Business Associations (813910), Social Advocacy Organizations (8133)
- SIC
- Services-Membership Organizations (8600), Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- Multilateral Global Health Agencies (UN/IFIs) (HLAJAKAA)
- akta.pro secondary industries
- Public Health Governance, Interagency Coordination & Partnerships (HLAJAMAD), Health Systems Strengthening & Universal Health Coverage (UHC) (BPADAIAE)
Keywords
Where PHAEUROPE is headquartered
LocationHeadquarters
- HQ city
- Vienna
- HQ country
- Austria
- HQ region
- Europe
Offices1 record
Markets served
PHAEUROPE business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Sponsorships and Grants: PHA Europe operates primarily through pharmaceutical company sponsorships, grants from the European Commission, and donations. The organization states it raises necessary means through support from pharmaceutical firms and other sponsors, as well as voluntary private donations.
- Donations: The organization accepts donations from individuals and organizations to support its mission of enhancing awareness of PH across Europe and promoting optimal standards of care.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels8 records
PHAEUROPE product offering
Product offeringCore offering
PHA Europe is a pan-European patient advocacy organization that represents people living with pulmonary hypertension through a network of 33 national member associations across 27 European countries. Its core offering is the coordination of awareness campaigns (World PH Day, O2Kids, Rare Disease Day), educational resources (Mariposa Journal, PH: It's Personal, Time to Talk, PH Human), the annual APHEC conference, capacity building for member associations, and policy advocacy at the European Parliament and EU institutions.
Product overview
PHAEUROPE is a non-profit patient organization representing pulmonary hypertension patients across Europe. It operates a portfolio of educational platforms and awareness programs rather than a traditional product. Key offerings include the Mariposa Journal (bi-annual publication), PH Human (educational platform for patients, carers, and healthcare professionals), PH: It's Personal (PAH and CTEPH educational materials), and the Time to Talk program. The organization runs major awareness campaigns including World Pulmonary Hypertension Day and the O2Kids campaign. PHAEUROPE also maintains the Bel Air Center (online PH platform) and the Find Your Specialist directory covering 33 European countries. Annual activities include the APHEC conference, collaborative educational programs with pharmaceutical sponsors, and advocacy initiatives.
Differentiator
Problem solved
Functional benefit
Brands
- World Pulmonary Hypertension Day (WPHD): Annual awareness campaign to raise visibility of pulmonary hypertension, first organized in 2012
- APHEC
- Mariposa Journal
- O2Kids
- Bel Air Center
- White Spot Program
Products and services
- Mariposa Journal A biannual magazine published by PHA Europe that reflects on advocacy work, collaboration efforts, and patient voices related to pulmonary hypertension, available to patients, member associations, healthcare professionals, and supporters.
- Bel Air Center An innovative online PH platform developed by PHA Europe that provides resources, educational content, and community support for pulmonary hypertension patients and their families.
- PH Human A collaborative educational platform that combines patient, carer, and healthcare professional resources for pulmonary hypertension education, developed with sponsors and supporting PHA Europe's educational mission.
- PH: It's Personal PAH and CTEPH educational materials for patients and carers developed in partnership with sponsors, providing personalized information about pulmonary hypertension.
- Time to Talk A collaborative educational program providing patient and carer resources as well as PHA Europe member resources, focused on conversation and engagement around pulmonary hypertension.
- O2Kids Campaign An awareness campaign featuring children with pulmonary hypertension designed to raise visibility of pediatric PH and the experiences of affected families, with videos reaching over 1,050,000 views.
- World Pulmonary Hypertension Day Annual global awareness day for pulmonary hypertension, first organized in Madrid in 2012, coordinated in collaboration with patient associations worldwide. The 2025 campaign reached 6.1 million impressions with 25,000+ engagements.
- Annual PH European Conference (APHEC) Annual conference organized by PHA Europe that brings together PH specialists, patient associations, and healthcare professionals across Europe for education and networking.
- Find Your Specialist A directory tool allowing patients to find PH specialists across 33 European countries, facilitating access to expert pulmonary hypertension care.
- Infographics Visual educational materials about pulmonary hypertension with over 5,000 views, providing accessible information for patients, carers, and healthcare professionals.
Quantifiable outcome
- Reduced diagnostic delay from average 3+ years to approximately 18 months through awareness campaigns
- +2 more outcomes
Companies that use PHAEUROPE
Customer profileNamed customers14 records
Segments4 records
Ideal customer profiles4 records
PHAEUROPE technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
PHAEUROPE partnerships and signals
Strategic signalPartnerships
22 partnerships are on record, tiered minor, core and moderate.
- AllRock BiominorPharmaceutical company dedicated to advancing therapies for cardiopulmonary diseases. Listed as a sponsor of PHA Europe.
- AOP Health (AOP Orphan)coreDevelops and investigates therapy options for patients with rare diseases including pulmonary hypertension. Major pharmaceutical sponsor of PHA Europe.
- Cereno ScientificminorPharmaceutical company focused on cardiovascular disease treatments. Listed as a sponsor of PHA Europe.
- FerrercoreInternational biopharmaceutical group. Co-hosts the IMPACHT conference and provides support for patient education programs. PHA Europe delivers presentations at Ferrer-organized medical conferences.
- Global Allergy & Airways Patient Platform (GAAPP)moderateEmpowers patients with allergies, airways, and atopic disease. Collaboration on respiratory patient advocacy and awareness campaigns.
- Gossamer BiominorClinical-stage biopharmaceutical company focused on pulmonary hypertension. Listed as a sponsor of PHA Europe.
- Johnson & Johnson Innovative MedicinecoreMajor pharmaceutical company with PH therapies. Listed as a sponsor of PHA Europe with significant support for patient advocacy initiatives.
- LiquidiaminorPharmaceutical company focused on pulmonary hypertension treatments. Listed as a sponsor of PHA Europe.
- MSDmoderateGlobal pharmaceutical company. Listed as a sponsor of PHA Europe.
- OrphaCareminorProvider of innovative technologies and progressive therapy concepts for rare diseases. Listed as a sponsor of PHA Europe.
- European Respiratory Society (ERS)coreLeading professional organization for respiratory medicine. PHA Europe collaborates with ERS on guidelines, congress participation, and respiratory health advocacy. ERS endorsed PHA Europe's Call to Action.
- European Lung Foundation (ELF)coreOrganization uniting patients, public, and respiratory professionals to promote lung health. PHA Europe participates in ELF Networking Day and CRC CONNECT initiatives.
- European Lung Health Group (ELHG)coreCoalition of respiratory patient organizations and societies. PHA Europe is a member and actively participates in High-Level Forums on Lung Health advocating for EU lung health policy.
- European Patients' Forum (EPF)moderateUmbrella organization representing 78 patient organizations across Europe. PHA Europe participates in EPF congresses and AGM, contributing to patient advocacy initiatives.
- European Pulmonary Fibrosis Federation (EU-PFF)moderateFederation focused on pulmonary fibrosis. PHA Europe participates in EU-PFF summits and collaborates on respiratory health advocacy given overlap between PF and PH conditions.
- Pulmonary Vascular Research Institute (PVRI)coreGlobal organization with 6,300+ members in 103 countries dedicated to pulmonary vascular research. PHA Europe collaborates on PH Global Survey (PHGPS), participates in PVRI congresses, and presents at their meetings.
- ERN-LUNGcoreEuropean Reference Network for rare lung diseases. PHA Europe participates in ERN-LUNG Board meetings and collaborates on expert center standards and patient care.
- ChiesimoderateResearch-oriented international biopharmaceutical group. Listed as a sponsor of PHA Europe.
- Inhibikase TherapeuticsminorPharmaceutical company developing treatments for pulmonary hypertension and related conditions. Listed as a sponsor of PHA Europe.
- InsmedmoderateBiopharmaceutical company focused on rare diseases including pulmonary hypertension. Listed as a sponsor of PHA Europe.
- PulmovantminorCompany committed to transforming lives of patients with pulmonary diseases. Listed as a sponsor of PHA Europe.
- Respira TherapeuticsminorCompany focused on pulmonary hypertension treatments. Listed as a sponsor of PHA Europe.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
PHAEUROPE competitors and assessment
Company assessmentDirect peers
- European Patients' Forum (EPF): Umbrella representing 78 chronic-disease patient organizations across Europe. Direct peer in patient advocacy at EU level, congress organization, and policy engagement on cross-cutting issues like health data and access to medicines.
- EURORDIS - Rare Diseases Europe: European umbrella of rare-disease patient organizations. Direct peer as a Brussels-based federation coordinating national member associations, engaging EU institutions on rare-disease policy, and advocating on access to therapies — operating model closely mirrors PHA Europe's structure.
- European Lung Foundation (ELF): Patient-facing arm of the European Respiratory Society that unites patients and respiratory professionals. Strategic partner of PHA Europe on lung-health policy; peer because it coordinates patient input across respiratory conditions and engages EU policymakers in similar forums.
- Cystic Fibrosis Europe: European umbrella of national cystic fibrosis patient associations. Comparable federated advocacy model, EU policy engagement, and pharma-sponsored educational programming for a rare respiratory disease across Europe.
- Pulmonary Vascular Research Institute (PVRI): Global research network of 6,300+ members across 103 countries focused on pulmonary vascular disease. Direct peer as a research-driven counterpart with overlapping congresses (e.g., PHGPS survey) and shared scientific committee engagement.
- Global Allergy & Airways Patient Platform (GAAPP): International alliance of patient organizations in allergy, asthma, and airways disease. Peer as an advocacy umbrella working with pharma sponsors and policymakers on respiratory conditions, with which PHA Europe formally collaborates.
- European Pulmonary Fibrosis Federation (EU-PFF): European umbrella of pulmonary fibrosis patient associations. Closest disease-area peer given the clinical and patient-journey overlap between PF and PH, and a confirmed collaboration partner of PHA Europe on respiratory advocacy.
Broad incumbents
- European Respiratory Society (ERS): Leading European professional society in respiratory medicine. Peer because it co-endorses PH clinical guidelines, runs the ERS Congress where PHA Europe presents, and shapes research and policy direction in the same disease area.
- ERN-LUNG (European Reference Network for Rare Respiratory Diseases): EU-funded network coordinating expert centers for rare lung diseases including PH. Peer as a multi-stakeholder platform influencing European reference-center standards and patient care pathways in PH.
- Pulmonary Hypertension Association (PHA US): The largest global PH patient-advocacy organization, founded in the US. Directly comparable to PHA Europe in mission (awareness, support, research) and activities (patient conferences, advocacy, support groups), but with a larger budget and North American geographic focus.
Market position
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
PHAEUROPE social profiles
Digital presencePHAEUROPE financial estimates
Financial estimateRevenue estimate
Valuation estimate
PHAEUROPE leadership team
Management profileNumber of profiles
Profiles3 records
PHAEUROPE funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PHAEUROPE M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PHAEUROPE
What does PHAEUROPE do?
PHA Europe is a pan-European patient advocacy organization that represents people living with pulmonary hypertension through a network of 33 national member associations across 27 European countries. Its core offering is the coordination of awareness campaigns (World PH Day, O2Kids, Rare Disease Day), educational resources (Mariposa Journal, PH: It's Personal, Time to Talk, PH Human), the annual APHEC conference, capacity building for member associations, and policy advocacy at the European Parliament and EU institutions.
Is PHAEUROPE a public or private company?
PHAEUROPE is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was PHAEUROPE founded?
PHAEUROPE was founded in -1. It employs 1 to 10 people.
Where is PHAEUROPE based?
PHAEUROPE is headquartered in Vienna, Austria, in the Europe region.
How does PHAEUROPE make money?
Two revenue lines are on record. Sponsorships and Grants are the primary driver. The others are donations.
Who are PHAEUROPE's main competitors?
Direct peers on record are European Patients' Forum (EPF), EURORDIS - Rare Diseases Europe, European Lung Foundation (ELF), Cystic Fibrosis Europe, Pulmonary Vascular Research Institute (PVRI), Global Allergy & Airways Patient Platform (GAAPP) and European Pulmonary Fibrosis Federation (EU-PFF). Broad incumbents are European Respiratory Society (ERS), ERN-LUNG (European Reference Network for Rare Respiratory Diseases) and Pulmonary Hypertension Association (PHA US).
Does PHAEUROPE have an API?
No public API is recorded for PHAEUROPE.
What industry is PHAEUROPE in?
PHAEUROPE's product category is Patient Advocacy Services. Its primary akta.pro industry code is HLAJAKAA, Multilateral Global Health Agencies (UN/IFIs), with a secondary code of HLAJAMAD, Public Health Governance, Interagency Coordination & Partnerships. Its NAICS code is 813910 and its SIC code is 8600.